↓ Skip to main content

Dove Medical Press

Article Metrics

Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease

Overview of attention for article published in Neuropsychiatric Disease and Treatment, March 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
39 Mendeley
Title
Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease
Published in
Neuropsychiatric Disease and Treatment, March 2014
DOI 10.2147/ndt.s45143
Pubmed ID
Authors

Ming-Jang Chiu, Ling-Yun Fan

Abstract

It has been estimated that 35.6 million people globally had dementia in 2010 and the prevalence of dementia has been predicted to double every 20 years. Thus, 115.4 million people may be living with dementia in 2050. Alzheimer's disease (AD) is the leading cause of dementia and is present in 60%-70% of people with dementia. Unfortunately, there are few approved drugs that can alleviate the cognitive or behavioral symptoms of AD dementia. Recent studies have revealed that pathophysiological changes related to AD occur decades before the appearance of clinical symptoms of dementia. This extended preclinical phase of AD provides a critical chance for disease-modifying agents to halt or delay the relentless process of AD. Although several trials targeting various pathological processes are ongoing, the examination of the combined use of different approaches to combat AD seems warranted. In this article, we will review current therapies, future strategies, and ongoing clinical trials for the treatment of AD with a special focus on combination therapies. Furthermore, preventive strategies for cognitively normal subjects in the presymptomatic stages of AD will also be addressed. In this review, we discuss current hypotheses of the disease process. In the decades since the approval of cholinesterase inhibitors, no new drug has ultimately demonstrated clear success in clinical trials. Given the difficulties that have been encountered in attempts to identify a single drug that can treat AD, we must pursue effective multi-target strategies, ie, combination therapies. The combination of cholinesterase inhibitors and memantine is considered well tolerated and safe, and this combination benefits patients with moderate-to-severe AD. In contrast, with the exception of adjuvant therapies of conventional drugs, combinations of different disease-modifying agents with different mechanisms may have promising synergic effects and benefit cognition, behavior, and daily living function.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 21%
Student > Master 8 21%
Student > Bachelor 7 18%
Researcher 6 15%
Professor > Associate Professor 2 5%
Other 7 18%
Unknown 1 3%
Readers by discipline Count As %
Medicine and Dentistry 15 38%
Psychology 7 18%
Agricultural and Biological Sciences 7 18%
Biochemistry, Genetics and Molecular Biology 3 8%
Nursing and Health Professions 2 5%
Other 4 10%
Unknown 1 3%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 November 2017.
All research outputs
#4,046,599
of 14,533,317 outputs
Outputs from Neuropsychiatric Disease and Treatment
#581
of 2,427 outputs
Outputs of similar age
#49,183
of 189,321 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#25
of 69 outputs
Altmetric has tracked 14,533,317 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,427 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,321 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.